Clusterin is a chaperone protein that is upregulated in response to chemotherapy and might mediate resistance, Now, data from SYNERGY, a phase III randomized-controlled trial indicate that custirsen, an antisense oligonucleotide that inhibits clusterin production, does not improve the efficacy of docetaxel plus prednisone in patients with metastatic, castration-resistant prostate cancer.